Home / Stocks / Neuland Lab Ltd.
NEULANDLAB

Neuland Lab Ltd. Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹21,102.0

Change

-353.0 (-1.65%)

Open

₹21,400.0

Prev. Close

₹21,455.0

Day High

₹21,535.0

Day Low

₹21,019.0

Volume Analysis

Traded

34,815

Delivered

18,232

Delivery %

52.37%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (21.2%)
  • •Strong operating margin (31.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year EPS growth (30.6%)
  • •Strong 3-year revenue growth (19.3%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹21,934.34 ₹21,734.67 ₹21,418.34 ₹21,218.67 ₹20,902.34 ₹20,702.67 ₹20,386.34
Fibonacci ₹21,734.67 ₹21,537.56 ₹21,415.78 ₹21,218.67 ₹21,021.56 ₹20,899.78 ₹20,702.67
Camarilla ₹21,243.9 ₹21,196.6 ₹21,149.3 ₹21,218.67 ₹21,054.7 ₹21,007.4 ₹20,960.1

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+40.12%

1 Week

+0.86%

1 Month

+11.21%

3 Months

-9.44%

6 Months

+26.41%

1 Year

+26.22%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹3,177.84

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

19.61%

Net margin 19.64% × asset turnover 0.67x × equity multiplier 1.49x

Company Overview

Sector

Healthcare

Market Cap

₹27,106 Cr

P/E (TTM)

59.9

ROE

21.2%

Book Value

₹1,582.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Neuland Lab Ltd. holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 68/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (21.2%); strong operating margin (31.0%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

68/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

95

Valuation

0

Cash Flow

31

Corporate Governance

50

Momentum

76

Institutional Ownership

59

Business Quality

96

Risk & Volatility

60

Liquidity

80

From Screener.in

  • +Company is expected to give good quarter
  • +Company has delivered good profit growth of 38.5% CAGR over last 5 years
  • −Stock is trading at 13.4 times its book value
  • −Promoter holding has decreased over last quarter: -0.36%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Transcript of the Earnings Call conducted on November 3, 2026

Management to attend JM Financial Annual India Conference in Mumbai on November 17, 2026.

KFin Technologies’ corporate office shifts to Kokapet, Hyderabad from December 1, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 418 393 385 440 311 398 328 293 514 440 776 642 450
Expenses + 280 272 278 316 249 311 277 258 359 363 469 419 352
Operating Profit 137 121 107 123 62 87 51 34 156 77 307 223 98
OPM % 33.0% 31.0% 28.0% 28.0% 20.0% 22.0% 16.0% 12.0% 30.0% 18.0% 40.0% 35.0% 22.0%
Other Income + 3 2 5 25 4 60 7 8 2 8 12 8 8
Interest 4 4 4 3 1 2 2 5 5 7 7 7 7
Depreciation 15 15 16 16 16 16 17 20 23 24 25 27 29
Profit before tax 122 104 92 130 49 128 39 18 129 54 287 198 69
Tax % 27.0% 22.0% 27.0% 25.0% 34.0% 20.0% 29.0% 21.0% 25.0% 26.0% 26.0% 25.0% 25.0%
Net Profit + 89 81 68 98 33 102 28 14 97 41 213 148 52
EPS in Rs 70 63 53 76 26 79 22 11 75 32 166 115 40
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 42 46 -5 21 -26 1 -15 -33 65 10 136 119 -13

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 469 510 579 527 667 763 937 951 1,191 1,559 1,477 2,023 2,307
Expenses + 402 430 472 477 608 661 790 807 918 1,096 1,146 1,443 1,602
Operating Profit 67 80 106 51 58 102 147 144 273 463 331 580 705
OPM % 14.0% 16.0% 18.0% 10.0% 9.0% 13.0% 16.0% 15.0% 23.0% 30.0% 22.0% 29.0% 31.0%
Other Income + 0 2 1 4 3 4 16 0 9 12 90 25 36
Interest 27 24 21 19 16 22 18 14 13 14 8 24 28
Depreciation 15 16 19 22 26 31 40 49 53 60 66 92 104
Profit before tax 25 42 67 14 20 53 105 82 216 401 346 489 609
Tax % 36.0% 36.0% 30.0% 13.0% 19.0% 69.0% 23.0% 22.0% 24.0% 25.0% 25.0% 26.0% —
Net Profit + 16 27 47 12 16 16 81 64 164 300 260 364 453
EPS in Rs 18 31 53 14 13 13 63 50 127 234 203 284 353
Dividend Payout % 8.0% 7.0% 0.0% 0.0% 0.0% 16.0% 8.0% 10.0% 8.0% 6.0% 6.0% 12.0% —
Sales growth 1 9 14 -9 26 14 23 2 25 31 -5 37 50

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 152 178 537 549 686 697 774 828 981 1,270 1,512 1,862 2,017
Borrowings + 188 182 192 319 231 264 182 241 128 95 157 301 342
Other Liabilities + 162 155 148 194 200 257 356 302 457 454 498 754 658
Total Liabilities 512 524 886 1,071 1,130 1,231 1,325 1,383 1,580 1,833 2,180 2,930 3,030
Fixed Assets + 123 139 466 475 542 653 716 767 758 824 955 1,177 1,278
CWIP 41 40 20 126 104 24 17 20 41 46 48 211 284
Investments 7 7 8 8 8 8 7 4 1 1 109 2 2
Other Assets + 340 337 393 463 476 547 585 592 781 962 1,068 1,541 1,465
Total Assets 512 524 886 1,071 1,130 1,231 1,325 1,383 1,580 1,833 2,180 2,930 3,030
Equity Capital 9 9 9 9 13 13 13 13 13 13 13 13 13

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 13 45 39 11 70 57 189 60 237 261 317 347
Cash from Investing Activity + -14 -20 -42 -116 -77 -49 -84 -95 -61 -150 -298 -423
Cash from Financing Activity + 1 -24 0 105 12 -5 -114 38 -136 -69 25 21
Net Cash Flow 0 1 -4 0 5 3 -9 3 40 42 44 -55
Free Cash Flow -1 26 -2 -121 7 9 84 -37 173 119 112 -50
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 33 70 52 28 128 61 132 56 103 81 119 78

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 32.8% → 32.26%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 38.1% 35.88% 34.77% 34.12% 33.96% 33.85% 33.67% 32.8% 31.76% 31.08% 29.79% 29.55%
Promoters 32.8% 32.74% 32.72% 32.64% 32.68% 32.67% 32.67% 32.64% 32.63% 32.63% 32.62% 32.26%
Government 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.0% 0.0% 0.0% 0.0%
FII 22.69% 24.43% 25.72% 26.46% 23.86% 22.12% 21.69% 20.6% 20.9% 20.46% 21.08% 21.93%
DII 6.02% 6.54% 6.39% 6.38% 9.09% 10.97% 11.57% 13.55% 14.72% 15.84% 16.52% 16.25%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Neuland Lab Ltd. (this stock) 27,106 59.9 13.35 21.2%
Rubicon Research Limited 27,764 85.5 19.59 27.0%
Krishna Inst Of Med Sci L 31,903 157.0 8.11 11.3%
Granules India Limited 22,226 31.7 3.39 13.8%
Acutaas Chemicals Limited 32,281 73.5 17.37 24.0%
Piramal Pharma Limited 32,557 — 4.0 -3.83%
Wockhardt Limited 32,944 82.4 6.39 6.11%

Which Mutual Funds Hold Neuland Lab Ltd.?

Frequently Asked Questions about Neuland Lab Ltd.

Community Sentiment

What are other investors saying about Neuland Lab Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.